Projecting future drug expenditures--2011

Doloresco, Fred; Fominaya, Cory; Schumock, Glen T.; Vermeulen, Lee C.; Matusiak, Linda; Hunkler, Robert J.; Shah, Nilay D.; Hoffman, James M.
May 2011
American Journal of Health-System Pharmacy;5/15/2011, Vol. 68 Issue 10, p921
Academic Journal
Purpose. Drug expenditure trends in 2009 and 2010, projected drug expenditures for 2011, and factors likely to influence drug expenditures are discussed. Summary. Various factors are likely to influence drug expenditures in 2011, including drugs in development, the diffusion of new drugs, generic drugs, health care reform, and biosimilars. Two distinct patterns of drug expenditures continue to exist. The dominant trend over the past several years is substantial moderation in expenditure growth for widely used drugs, primarily due to the ongoing introduction of generic medications for high-cost, frequently used medications and the influence of the economic downturn. The second pattern is substantial increases in expenditures for specialized medications, particularly in the outpatient setting. The influence of health care reform, the economy, and the emergence of biosimilars will be important trends to follow over the next several years, but they are unlikely to have substantial impact on drug expenditures in 2011. From 2008 to 2009, total U.S. drug expenditures increased by 5.2%, with total spending rising from $284.8 billion to $299.5 billion. Growth in drug expenditures in clinics grew by 5.1% from 2008 to 2009. Hospital drug expenditures increased at the moderate rate of 2.8% from 2008 to 2009; through the first nine months of 2010, hospital drug expenditures increased by only 0.8% compared with the same period in 2009. Conclusion. For 2011, we project a 3-5% increase in drug expenditures in outpatient settings, a 4-6% increase in expenditures for clinic-administered drugs, and a 1-3% increase in hospital drug expenditures.


Related Articles

  • A cloudy dawn for biosimilars. Goozner, Merrill // Modern Healthcare;11/23/2015, Vol. 45 Issue 47, p0024 

    The article discusses the risks associated with the arrival of biogenerics, which healthcare cost-control advocates expected when the Biologics Price Competition and Innovation Act was set up onto the Affordable Care Act. Topics cited include the impossibility of biosimilars generating the same...

  • Safety Concerns About Possible Drug Imports Are Reiterated.  // Chain Drug Review;8/3/2009, Vol. 31 Issue 13, p113 

    The article focuses on the effort of the Pharmaceutical Research and Manufacturers of America (PhRMA) to oppose the policy allowing reimportation of drugs to be a key component of health care reform in the U.S. According to PhRMA, it is important to keep focus on comprehensive health reform to...

  • Saving your health-care dollars.  // Consumer Reports on Health;Jan2009, Vol. 21 Issue 1, p3 

    The article provides tips on how to lower medical expenses in the U.S. It notes that telling doctors that cost matters will make them hold off on nonessential tests and treatments and cut drug costs by just merely prescribing generic than brand-name medications. Furthermore, looking for discount...

  • Biosimilars: time for an approval pathway in the US.  // PharmaWatch: Biotechnology;Apr2009, Vol. 8 Issue 4, p11 

    In this article the author discusses another bill received by the U.S. Congress that seeks to establish a biosimilars approval pathway in the country. He asserts that the proposed bill will be contradicted by prescription drug manufacturers. He adds that the industry is under pressure to find a...

  • Generic prescribing is expected to save Spain €2bn a year. Rada, Aser García // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;7/30/2011, Vol. 343 Issue 7817, p228 

    The article informs that a medical law in Spain now requires that doctors should prescribe generic drugs wherever possible and it is expected that this strategy will save 2 billion euros a year for the health service.

  • The Generic Drug Rip Off. FALOON, WILLIAM // Life Extension;Aug2009, Vol. 15 Issue 8, p7 

    The article offers the author's views on the rising cost of prescription drugs in the present health care cost crisis in the U.S. He focuses on the economic factors in the country that result in pharmaceutical companies raising the cost of universal medicines and medical facilities. He states...

  • MA plans face further cuts, more quality expectations. Wechsler, Jill // Managed Healthcare Executive;Apr2010, Vol. 20 Issue 4, p9 

    In this article, the author discusses the revisions of methods for computing payments to Medicare Advantage (MA) plans which is one of the provisions in the health care reform legislation in the U.S. The author claims that proposed revisions to benchmarks and bids will be cutting cost by more...

  • Is this utopia? MCLAUGHLIN, NEIL // Modern Healthcare;4/18/2011, Vol. 41 Issue 16, p22 

    The author comments on the Medicare and Medicaid plans unveiled by U.S. Representative Paul Ryan (R-Wis.), chairman of the U.S. House Budget Committee, which would convert Medicare into a voucher program and would call for repealing the Patient Protection and Affordable Care Act. The impact of...

  • Palm Beach County, Fla.  // American City & County;Dec93, Vol. 108 Issue 13, p19 

    Reports on the savings derived by Palm Beach County, Florida taxpayers as a result of switching from brand name to generic drugs. County program to reduce costs and promote new revenues; Total annual savings; Combination of one-time savings and new revenues.

  • New healthcare payment models to shape drug coverage, costs, and expenditures. Wechsler, Jill // Formulary;Nov2012, Vol. 47 Issue 11, p405 

    The article presents an overview of innovative health care system payment models which have resulted from or will result from health care reform in the U.S. and will have an impact on drug expenditures, costs and coverage in 2012 and beyond. An increase in the use of generic drugs and a demand...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics